Spring Bank Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, SBPH, Spring Bank Pharmaceuticals Inc, priceseries

Spring Bank Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
5.22
Close
4.84
High
5.22
Low
4.60
Previous Close
1.21
Daily Price Gain
3.63
YTD High
18.93
YTD High Date
Nov 13, 2017
YTD Low
0.80
YTD Low Date
Mar 16, 2020
YTD Price Change
-6.26
YTD Gain
-56.40%
52 Week High
18.93
52 Week High Date
Nov 13, 2017
52 Week Low
0.80
52 Week Low Date
Mar 16, 2020
52 Week Price Change
-6.26
52 Week Gain
-56.40%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 9. 2017
7.66
Mar 6. 2017
9.75
16 Trading Days
27.27%
Link
LONG
Apr 27. 2017
9.20
May 30. 2017
12.31
22 Trading Days
33.77%
Link
LONG
Nov 3. 2017
15.73
Nov 14. 2017
16.90
7 Trading Days
7.45%
Link
LONG
Feb 23. 2018
12.05
Mar 23. 2018
14.88
20 Trading Days
23.52%
Link
LONG
Oct 3. 2018
12.05
Oct 19. 2018
13.50
12 Trading Days
12.04%
Link
LONG
May 13. 2019
7.10
May 15. 2019
7.54
2 Trading Days
6.20%
Link
LONG
Jul 16. 2019
5.07
Jul 18. 2019
5.38
2 Trading Days
6.21%
Link
LONG
Nov 26. 2019
3.25
Dec 5. 2019
3.52
6 Trading Days
8.38%
Link
LONG
Apr 8. 2020
1.02
Apr 30. 2020
1.29
15 Trading Days
26.81%
Link
LONG
Jul 17. 2020
1.63
Jul 30. 2020
1.82
9 Trading Days
11.96%
Link
LONG
Nov 4. 2020
1.20
Nov 6. 2020
1.26
2 Trading Days
5.21%
Link
Company Information
Stock Symbol
SBPH
Exchange
NasdaqCM
Company URL
http://www.springbankpharm.com
Company Phone
508-473-5993 X119
CEO
Martin J. Driscoll
Headquarters
Massachusetts
Business Address
86 SOUTH STREET, HOPKINTON, MA 01748
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001566373
About

Spring Bank Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of a novel class of orally bioavailable therapeutics using proprietary Small Molecule Nucleic Acid Hybrid chemistry platform. Its pipeline SB 9200 HBV, deals with the treatment of Hepatitis B virus. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 07, 2002 and is headquartered in Milford, MA.

Description

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its SMNH compounds are small segments of nucleic acids that are design to target and modulate the activity of specific proteins implicated in various disease states. The company's lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus. It also develops SMNH product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers; and SB 9400, SB 9941 and SB 9946 preclinical product candidates for viral diseases. The company has an agreement with Arrowhead Pharmaceuticals, Inc. to collaborate on the study of the combined use of SB 9200 and small interfering ribonucleic acid product pipeline for the treatment of chronic hepatitis B virus (HBV); and Arbutus Biopharma Corporation to collaborate on the preclinical study of the combined use of SB 9200 and AB-423, a capsid assembly inhibitor for the treatment of chronic HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading